908 Devices Inc. filings document an operating company that sells common stock under MASS on the Nasdaq Global Market and reports on handheld chemical analysis tools used in health, safety and defense technology markets. Form 8-K reports furnish operating and financial results, revenue outlook materials, material-event disclosures, material agreements, capital-structure matters and related exhibits.
Proxy materials cover annual meeting voting matters, including director elections, auditor ratification, executive compensation votes and the frequency of future advisory compensation votes. The filing record also includes governance disclosures tied to board composition, annual meeting procedures, shareholder voting mechanics and emerging growth company status.
908 Devices Inc. director ELOI FENEL M reported equity awards and an option exercise-related share delivery. On June 10, 2026, 14,083 Restricted Stock Units vested and converted into 14,083 shares of Common Stock, bringing direct holdings to 40,897 shares.
On June 11, 2026, the director received a grant of 6,209 stock options with an exercise price of $8.22 per share, expiring on June 10, 2036, which vest in substantially equal monthly installments over the 12 months following June 11, 2026. The director was also granted 13,656 Restricted Stock Units that vest in full on June 11, 2027 or the day prior to the 2027 annual stockholders’ meeting, with prorated vesting if service ends earlier.
908 Devices Inc. director Keith Crandell reported equity compensation activity and a derivative exercise. On June 11, 2026, he received a stock option grant for 6,209 shares of Common Stock at an exercise price of $8.22 per share, vesting in equal monthly installments over 12 months, and a grant of 13,656 Restricted Stock Units (RSUs) that vest in full on June 11, 2027 or the day prior to the 2027 annual meeting, subject to continued service and prorating on earlier termination. On June 10, 2026, 14,083 RSUs became fully vested and were converted into 14,083 shares of Common Stock, leaving 39,374 shares of Common Stock held directly after the transaction. An entity, ARCH Venture Fund VII, L.P., associated through layered general partners with Crandell as a managing director, holds 5,725,045 shares of Common Stock indirectly; he may be deemed to beneficially own these securities but disclaims beneficial ownership except to the extent of his pecuniary interest.
908 Devices Inc. director Mark Spoto reported multiple equity compensation transactions. He received a grant of 6,209 stock options to buy Common Stock at an exercise price of $8.22 per share, which vest in substantially equal monthly installments over the 12 months following June 11, 2026 and expire on June 10, 2036.
He also received 13,656 Restricted Stock Units, each representing a contingent right to one share of Common Stock, that become fully vested on June 11, 2027 or the day before the 2027 annual stockholder meeting, with prorated vesting if his service ends earlier. Separately, 14,083 RSUs became fully vested on June 10, 2026 and were converted into 14,083 Common Stock shares, bringing his direct Common Stock holdings to 89,346 shares.
In addition, 3,599 Common Stock shares are held indirectly through Razor's Edge Ventures, LLC, where he is a managing member and may be deemed a beneficial owner, though he disclaims beneficial ownership beyond his pecuniary interest.
908 Devices Inc. reported the results of its 2026 Annual Meeting of Stockholders. As of the April 16, 2026 record date, 37,446,534 common shares were outstanding and entitled to vote, and 28,653,832 shares were present in person or by proxy, representing 76.52% of eligible shares and constituting a quorum.
Stockholders elected three Class III directors—Keith L. Crandell, Christopher Brown, Ph.D., and E. Kevin Hrusovsky—to serve until the 2029 annual meeting and until their successors are elected and qualified. Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2026.
In an advisory vote, stockholders approved the compensation of the company’s named executive officers. In a separate advisory vote on the frequency of future say-on-pay votes, stockholders favored holding the vote every one year. The board determined that future advisory votes on executive compensation will be held annually until the next required frequency vote.
908 Devices Inc. director Christopher D. Brown reported an open-market sale of 100 shares of Common Stock at $9.00 per share on June 4, 2026. After this transaction, he directly holds 875,459 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025.
908 Devices Inc. reports a beneficial ownership filing showing ownership of 1,883,206 shares of Common Stock, representing 4.94% of the class. The filing lists ARK Investment Management LLC and Catherine D. Wood as holders of the 1,883,206 shares, with signature dates of 06/05/2026.
The filing is a Schedule 13G/A and is labeled "Ownership of 5 Percent or Less of a Class." It discloses voting and dispositive power split: ARK holds sole voting and dispositive power for 1,883,206 shares while Catherine D. Wood holds shared voting and dispositive power for the same amount.
AWM Investment Company, Inc., as investment adviser to several funds, reported open-market sales of 908 Devices Inc. common stock held indirectly through limited partnerships. The transactions covered 39,782 shares at a weighted-average price of $8.9703 on June 4, 2026 and 2,500 shares at $8.95 on June 2, 2026. After these sales, entities advised by AWM reported holding 4,887,491 shares indirectly. AWM and its principals disclaim beneficial ownership of these shares except to the extent of their pecuniary interest.
908 Devices Inc. director Christopher D. Brown sold shares of company stock. On this Form 4, he reported an open-market sale of 20,000 shares of common stock at a weighted average price of $8.73 per share. After the transaction, he directly holds 875,559 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025.
MASS filed a Form 144 to sell 70,000 shares of Common Stock.
The notice lists multiple 10b5-1 sales by Christopher Brown: 30,000 shares on 05/28/2026 for $270,000, 20,000 shares on 05/06/2026 for $144,668, and earlier April sales totaling additional shares and proceeds.
AWM Investment Company, Inc., a 10% owner of 908 Devices Inc., reported open-market sales totaling 186,942 shares of common stock through a limited partnership on May 27–28, 2026. Sale prices ranged from about $8.25 to $8.66 per share, leaving 4,929,773 shares indirectly held afterward. AWM reports these holdings as investment adviser to several funds and disclaims beneficial ownership beyond its pecuniary interest.